Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B2acb29ef4e5e04cda125af1dbef1cfd7> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B2acb29ef4e5e04cda125af1dbef1cfd7 NCIT_P378 "NCI" @default.
- B2acb29ef4e5e04cda125af1dbef1cfd7 type Axiom @default.
- B2acb29ef4e5e04cda125af1dbef1cfd7 annotatedProperty IAO_0000115 @default.
- B2acb29ef4e5e04cda125af1dbef1cfd7 annotatedSource NCIT_C66944 @default.
- B2acb29ef4e5e04cda125af1dbef1cfd7 annotatedTarget "An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells." @default.